Top news of the week: 10.11.2020.
#biotechnology #lifesciences #pharmaceuticals #biospace #biopharma #workplace #coronavirus #COVID #innovation #inclusion
Career And Jobs
RT @MassBio: To celebrate outstanding support for #biotechnology education in MA, @MassBioEd is holding its 5th Annual Champions for Biotechnology Education Awards Reception on 11/18. Read our blog to see this year's honorees: https://t.co/eNZTaxZrvR
OpenMassBioEd Champions for Biotechnology Education
To celebrate outstanding support for biotechnology education in Massachusetts, MassBioEd is holding its 5th Annual Champions for Biotechnology Education Awards Reception on Wednesday, ...
Emerging Biotech Enhances CNS Focus Through a Strategic Acquisition
#biospace #lifesciences #biotechnology #pharmaceuticals
https://t.co/LA8fYWp6A5
OpenEmerging Biotech Enhances CNS Focus Through a Strategic Acquisition
On October 30, the company announced the acquisition of long-time collaborator Oscine Corp.
How COVID-19 is Catalyzing a Better, More Efficient Biopharma Environment
#biospace #lifesciences #biotechnology #pharmaceuticals #biopharma #COVID-19 #coronavirus #pandemic
https://t.co/GNejxo52W2
OpenHow COVID-19 is Catalyzing a Better, More Efficient Biopharma Environment
The COVID-19 pandemic changed the biopharma industry and the world irrevocably. The challenges will reverberate even after the pandemic ends, according to panelists at the Cell and Gene ...
UK's coronavirus vaccine taskforce chief faces questions over biotech fund https://t.co/PtWjxuiipV
OpenUK's coronavirus vaccine taskforce chief faces questions over biotech fund
Report claims Kate Bingham’s venture capital firm has invested in companies developing Covid-19 antibody cocktails
An ‘innocent bystander’ in the booming biotech investor world is writing a blank check for $100M. Who’s going to cash it?
https://t.co/bUPKYsH0qU
OpenAn ‘innocent bystander’ in the booming biotech investor world is writing a blank check for $100M. Who’s going to cash it?
Srini Akkaraju’s LinkedIn profile describes his work as a “biotech investor (aka innocent bystander)” with tongue-in-cheek modesty. But he’s been deeply steeped in the ways of venture ...
RT @AlexHarding7: For once, an informative poll: Biotech execs support a rigorous and stringent FDA approval process, in this case for AD. Strong FDA is in everyone's interest. - https://t.co/6AfLzjvprc
OpenThe Endpoints poll: A large majority of biopharma execs turn thumbs down on Biogen's controversial pitch for aducanumab
There’s a big vote looming at the end of the week as outside experts at the FDA put Biogen’s Alzheimer’s drug aducanumab on trial. But as far as the industry is concerned, most people in ...
SPACs Soar as Fast, Hassle-Free IPO Alternatives for Biotech Companies
#biospace #lifesciences #biotechnology #pharmaceuticals #workplace #culture #diversity #inclusion #innovation #SPAC
https://t.co/vnNOyA1hss
OpenSPACs Soar as Fast, Hassle-Free IPO Alternatives for Biotech Companies
Special purpose acquisition companies (SPACs) are resurging as a virtually hassle-free alternative to initial public offerings (IPOs). They’ve been around for years, but are just now ...
Biopharma Money on the Move: October 28 – November 3
#biospace #lifesciences #biotechnology #pharmaceuticals #Biopharma
https://t.co/Tx3iizYKF8
OpenBiopharma Money on the Move: October 28 – November 3
Find out which biopharma companies are raking in the cash this week, as companies from around the globe provide updates on their financing rounds and IPOs.